KAS
IMVT icon

Kemnay Advisory Services’s Immunovant IMVT Stock Holding History

Kemnay Advisory Services’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.5K Sell
791
-1,628
-67% -$49.6K ﹤0.01% 491
2026
Q1 		$60.1K Buy
2,419
+2,003
+481% +$51.9K 0.01% 219
2025
Q4 		$10.6K Buy
+416
New +$9.28K ﹤0.01% 735

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Kemnay Advisory Services's IMVT Position: Q2 2026 in Review

Kemnay Advisory Services reduced its Immunovant (IMVT) stake by 67% in Q2 2026, selling an estimated $49.6K and leaving 791 shares worth $30.5K. The position accounts for ﹤0.01% of the portfolio, ranked #491.

Kemnay Advisory Services first reported a position in IMVT in Q4 2025 and has held it in 3 quarters since. The position peaked at $60.1K in Q1 2026. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Kemnay Advisory Services held 791 shares of Immunovant worth $30.5K as of Q2 2026.
  • Kemnay Advisory Services sold 1,628 Immunovant shares in Q2 2026, an estimated $49.6K.
  • Immunovant made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q2 2026, its #491 holding.
  • Kemnay Advisory Services first reported a position in Immunovant in Q4 2025 and has held it in 3 quarters since.
  • Kemnay Advisory Services's Immunovant position peaked at $60.1K in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.